Participated · Series B · Apr 2026

D-Robotics was spun off from the AIoT division of Horizon Robotics in January 2024 and develops underlying computing platforms and general-purpose hardware and software infrastructure for consumer robots and embodied AI. Its current product lineup includes the RDK S600 robot computing development platform and embodied AI model systems HoloBrain and HoloMotion. The company promotes a “one brain, multiple forms” approach that it says enables the same model to be adapted across different types of robots, mirroring a "chip + toolchain + algorithm" strategy. D-Robotics reported shipments jumped 180% year-over-year and its customer base grew 200% last year. It has launched more than 100 robot products and built a developer community exceeding 100,000 users across the Asia-Pacific, Europe, and North America. The company did not disclose total shipment volumes or a revenue breakdown in the available reports.

Participated · Series B · Apr 2026

Syneron Bio develops macrocyclic peptide therapeutics using its proprietary, high-throughput Synova™ discovery platform. The company's pipeline is diversified across oncology, autoimmune, metabolic, and rare disease indications. Syneron Bio plans to use the Series B proceeds to further evolve and scale its intelligence-driven Synova™ platform and to accelerate progression of multiple core programs into clinical development. The financing, which strengthened the company's cash position, includes participation from global life-science funds, sovereign wealth, strategic corporates and existing shareholders. Syneron Bio highlights improving platform efficiency and success rates as central to its future discovery and development efforts. The company is headquartered in Beijing.

Participated · Seed · Mar 2026

Excalipoint Therapeutics is a clinical-stage biotechnology company focused on discovering and developing T-cell engager (TCE) therapies for oncology and immunology indications. Its pipeline includes tri- and multi-specific antibody programs such as EXP011 (CTM012) targeting DLL3/CD3/4-1BB—entered Phase I/II with first patient dosed in October 2025—EXP012 (CTM013) targeting CDH17/CD3/4-1BB, and additional programs (EXP016, EXP017, EP101, EXP015) built on its TOPAbody, Immune Shield, and Pro-TCE platform technologies. The company is led by CEO Lei Fang and CFO Jielun Zhu. Following the $68.7M Seed raise, Excalipoint intends to use the funds to advance its proprietary platforms and progress its pipeline programs through clinical development.

Participated · Series A · Mar 2026

Founded in 2023 and based in Menlo Park, Dify provides a visual workflow builder coupled with production-grade infrastructure for prompt management, tool integrations, knowledge retrieval, debugging, and API deployment. The platform sits between foundation models and business systems, enabling teams to transform domain-specific processes—such as document review, internal copilots, customer support automation, and invoice auditing—into maintainable AI workflows. Dify has become one of GitHub’s most-starred open-source repositories and now runs on more than 1.4 million machines worldwide. Over 2,000 teams and 280 enterprises, including Maersk, ETS, Anker Innovations, and Novartis, use its commercial offerings. The company plans to use new capital to integrate advanced agent capabilities, form a dedicated enterprise product team focused on performance and compliance, and launch community initiatives that lower adoption barriers. These efforts support a roadmap extending through 2026. The recent fundraise places Dify’s valuation at $180 million, underscoring strong market traction for its enterprise-grade AI workflow platform.

Participated · Series C · Mar 2026

QL Biopharma focuses on innovative drugs for chronic metabolic disorders, building a differentiated pipeline of ultra-long-acting, oral, and multi-target peptides to improve patient compliance. Its lead asset, ZT002 (a once-monthly injectable GLP-1RA), is in Phase III weight-loss trials in China after Phase II data showed 13.8 % weight reduction at 24 weeks with minimal GI-related dropouts. Additional programs include ZT006, an oral GLP-1 receptor agonist in Phase II for obesity, and ZT003, a GLP-1/FGF21 dual agonist in Phase I trials in Australia. The company also licenses its semaglutide biosimilar ZT001 to Tonghua Dongbao and Aimeike for diabetes and weight-management indications. Four in-house technology platforms (QLLong, QLOral, QLFold, and QLFusion) span R&D through commercial-scale production, backed by a recently approved manufacturing facility. Proceeds will accelerate clinical advancement, regulatory filings, and commercialization of its metabolic disease portfolio. No revenue or user metrics were disclosed in the articles.